Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90095


It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.

Study summary:

Etanercept, a biologic anti-TNF fusion protein, will be administered weekly or biweekly by perispinal injection to a maximum of 30 study subjects for a period of one year with serial testing of cognition and function.


Inclusion Criteria: - NINCDS-ADRDA Criteria for Alzheimer’s disease - CT or MRI consistent with AD Exclusion Criteria: - active infection - CHF - demyelinating disease - uncontrolled diabetes mellitus - vascular dementia - clinically significant neurologic disease other than AD - Hachinski >4 - history of lymphoma - TBC - wbc<2500 - platelets<100,000 - HCT<30 - pregnancy - premenopausal, fertile not on acceptable birth control - change in neuroactive medication within 4 weeks of study initiation



Primary Contact:

Principal Investigator
Edward L. Tobinick, M.D.
unaffiliated (Assistant Clinical Professor of Medicine, David Geffen School of Medicine at UCLA)

Backup Contact:


Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.